The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amgen Inc. (“Amgen” or “the Company”) (NASDAQ: AMGN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. As part of Amgen’s first quarter 2022 earnings release issued on April 27, 2022, the Company admitted that: “on April 18, 2022, Amgen received a notice of deficiency from the [Internal Revenue Service (‘IRS’)] for the 2013-2015 period proposing adjustments primarily related to the allocation of profits between certain of the Company’s entities in the United States and the U.S. territory of Puerto Rico,” which “seeks to increase Amgen’s U.S. taxable income for the 2013-2015 period by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest.” The Company also disclosed that the IRS has proposed a penalty of approximately $2 billion related to the deficiency. Based on this news, shares of Amgen fell sharply on April 28, 2022.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.